Startup Funding News
Explore funding rounds, the companies behind them and the investors taking part.
- Rounds
- 745 All time
- Disclosed funding
- $25.4B 610 disclosed amounts
- Median round
- $16M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| VD Vivid DxCompany profile Rapid infectious disease testing helping hospitals identify pathogens and guide antibiotic decisions Rapid infectious disease testing helping hospitals identify pathogens and guide antibiotic decisions | $15M | Seed | Healthtech | United Kingdom | Investors | |
| M MiraeCompany profile AI-driven continuous care platform for autoimmune disease and other complex chronic conditions AI-driven continuous care platform for autoimmune disease and other complex chronic conditions | $5.4M | Seed | Healthtech | United Kingdom | Investors | |
| NM Navi Medical TechnologiesCompany profile Develops ECG-guided catheter placement technology for neonatal and paediatric care Develops ECG-guided catheter placement technology for neonatal and paediatric care | A$6.8M | Undisclosed | Healthtech | Australia | Investors | |
| DT Dopl TechnologiesCompany profile Developing a robotic ultrasound platform for remote diagnostic exams. Developing a robotic ultrasound platform for remote diagnostic exams. | $6.3M | Seed | Healthtech | United States | Investors | |
| T UK healthtech startup using AI to cut lung disease test time | $19M | Undisclosed | Healthtech | United Kingdom | Investors | |
| PM AI-powered concierge primary care platform | $16M | Undisclosed | Healthtech | United States | Investors | |
| CH Automates the financial infrastructure of American healthcare | $120M | Series DSeries C+ | Healthtech | United States | Investors | |
| P PawPay turns any policy into pet insurance that pays vet directly | Undisclosed | Undisclosed | Healthtech, Fintech | United States | Investors | |
| CT Crystalys TherapeuticsCompany profile Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout | $130M | Series B | Healthtech, Biotech | United States | Investors | |
| NB N-Zyme BiomedicalCompany profile Developing first-in-class therapies targeting pepsin for reflux disease Developing first-in-class therapies targeting pepsin for reflux disease | $4.6M | Series A | Healthtech, Biotech | United States | Investors Undisclosed |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1General Catalyst
Baba, Disha (formerly Curelink), Thatch
23rounds2led - 2Y Combinator (YC)
Vitalize, Angle Health, Metriport
21rounds0led - 3Alumni Ventures
MintNeuro, Evvy, Hopscotch Primary Care
13rounds0led - 4Andreessen Horowitz (a16z)
Sharp Performance, General Medicine, Devoted Health
12rounds2led - 5Khosla Ventures
Even Healthcare, Abby Care, Rightway
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.
Browse rounds by topic
Geography
Featured selections
Nordic Foodtech Fund II pairs early capital with scientific expertise
An EIF pledge of up to €30m supports a fund targeting €80m for science-led agrifood companies.
Read the research →